Eli Lilly (LLY)
(Delayed Data from NYSE)
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 6:22 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$891.07 USD
+6.59 (0.75%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $891.10 +0.03 (0.00%) 6:22 PM ET
1-Strong Buy of 5 1
D Value F Growth B Momentum F VGM
Zacks News
Teva Migraine Candidate Succeeds in Second Phase III Study
by Zacks Equity Research
Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.
Novartis' (NVS) Tasigna Receives Label Update Nod in EU
by Zacks Equity Research
Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.
Novartis, Bristol-Myers Collaborate for Opdivo Combination
by Zacks Equity Research
Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.
Seattle Genetics Reports Updated Results on Cancer Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME).
Novartis Presents Data on Tafinlar-Mekinist Combination
by Zacks Equity Research
Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Pfizer Provides Final Update on Phase II Talazoparib Study
by Zacks Equity Research
Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity
Novartis Reports Positive Data on Breast Cancer Drug Kisqali
by Zacks Equity Research
Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali.
Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More
by Arpita Dutt
Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.
Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III
by Zacks Equity Research
Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.
The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana
Big Pharma Diabetes Drugs Not So Sweet. What's in Store?
by Zacks Equity Research
Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
Radius Health Osteoporosis Drug Positive in Phase III Study
by Zacks Equity Research
Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .
Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.
Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
by Zacks Equity Research
Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
by Arpita Dutt
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now
by Zacks Equity Research
It looks like a great stock to buy now.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One
Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
by Arpita Dutt
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.